Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Dose Escalation in Ankylosing Spondylitis (ASLeap)
NCT03350815Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Mar 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03350815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350815.